Eventide Asset Management IMVT Position
Exited11-Fund ConvergenceEventide Asset Management exited their position in Immunovant Inc. (IMVT) in Q2 2023, after holding the stock for 2 quarters.
The position was first reported in Q1 2023 and has been tracked across 2 quarterly 13F filings.
IMVT is a convergence signal: 11 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Batoclimab in 137 days (Aug 31, 2026), making the timing of Eventide's position particularly relevant.
Short interest stands at 18.6% of float with 15.9 days to cover, indicating significant bearish positioning against the stock.
About Immunovant Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Full company profile →Short Interest
18.6%
15.9 days to cover
Eventide Asset Management IMVT Position History
Frequently Asked Questions
Does Eventide Asset Management own IMVT?
No. Eventide Asset Management exited their position in Immunovant Inc. (IMVT) in Q2 2023. They previously held the stock for 2 quarters.
How many hedge funds own IMVT?
11 specialist biotech hedge funds currently hold IMVT, including Deep Track Capital, Perceptive Advisors, Baker Bros. Advisors and 8 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Eventide Asset Management first buy IMVT?
Eventide Asset Management's position in IMVT was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Eventide Asset Management's IMVT position increasing or decreasing?
Eventide Asset Management completely exited their IMVT position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
IMVTCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Eventide Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →